The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
Tempus AI, Inc. securityholder Eric Lefkofsky and affiliated entities have filed a notice for the proposed sale of up to 250,000 shares of Class A common stock through J.P. Morgan Securities LLC. The filing lists an aggregate market value for these planned sales of $10,727,500. Class A common stock outstanding is reported at 174,520,978 shares as of 07/28/2026; this is a baseline figure, not the amount being offered. The securities to be sold were originally acquired via stock compensation, direct cash investments in 2017 and 2020, and a donation of 50,000 shares from Blue Media LLC in 2025.
The filing also details sales of Class A common stock during the past three months, including 22,335 shares sold by Eric Lefkofsky for $984,303.45 on 05/19/2026, and multiple transactions by Blue Media, LLC and Gray Media, LLC. Blue Media, LLC reported sales of 133,000 shares for $6,210,943 on 05/27/2026 and 133,000 shares for $7,645,208.81 on 06/29/2026. Gray Media, LLC reported sales of 33,250 shares for $1,552,736 on 05/27/2026 and 33,250 shares for $1,911,302.20 on 06/29/2026.
Tempus AI, Inc. agreed to acquire Personalis, Inc. through a two-step merger structure. Merger Sub I will merge into Personalis, which will then merge into Merger Sub II, leaving Merger Sub II as a wholly owned subsidiary of Tempus. Personalis stockholders’ shares will be converted into the right to receive Tempus Class A common stock, with an exchange ratio based on the volume-weighted average price of Tempus Class A common stock over fifteen consecutive trading days before closing, or on per-share consideration in a specified Tempus transaction. The parties intend the deal to qualify as a tax reorganization under Section 368(a).
Closing is subject to Personalis stockholder approval, Nasdaq listing of the Tempus shares issued in the merger, effectiveness of a Form S-4 registration statement, HSR and other antitrust clearances, tax opinions, accuracy of representations, covenant compliance, and absence of specified material adverse effects. Personalis is bound by a no-shop covenant but may consider a Superior Proposal subject to notice, matching rights and, in certain cases, payment of a termination fee. Personalis may terminate if the Tempus Stock Price is below a $46.00 lower floor price during a short window before closing. If the Merger Agreement is terminated in certain circumstances, Personalis must pay Tempus a $76.8 million termination fee, and Tempus must pay Personalis a $76.8 million reverse termination fee if regulatory-related conditions fail primarily due to Tempus’ breaches and closing has not occurred by an initial outside date of April 20, 2027, subject to possible extensions.
Tempus AI, Inc. entered into a definitive agreement to acquire Personalis, Inc., valuing Personalis at an enterprise value of $1.5 billion, with shareholders receiving $16.25 per share. The deal, built on an existing MRD collaboration, combines Personalis’ tumor-informed minimal residual disease technology with Tempus’ multimodal data and AI-enabled precision oncology platform.
The consideration is a 100% stock transaction, with Tempus able to elect cash for up to 50% of the consideration; Personalis holders will receive a floating exchange ratio of Tempus shares, capped at 0.3356 per Personalis share. The price reflects a 6% premium to the prior closing price and a 28% premium to the unaffected 30‑day VWAP. Closing is expected in late 2026 or early 2027, subject to Personalis shareholder and regulatory approvals. Personalis reported preliminary Q2 revenue of $22.4 million and 10,384 clinical tests, a 33% sequential volume increase, highlighting MRD momentum in a cited $20 billion market opportunity.
Tempus AI agreed to acquire Personalis through a two-step merger structure that will leave Personalis as an indirect, wholly owned Tempus subsidiary. The deal provides $16.25 per share of Personalis common stock, implying $1.5 billion enterprise value net of Tempus’ existing ownership.
Consideration is structured as 100% Tempus stock, while giving Tempus the option to pay up to 50% of the consideration in cash. Personalis shareholders will receive a floating exchange ratio of Tempus shares per Personalis share, capped at 0.3356. The boards of both companies approved the transaction, which is targeted to close in late 2026 or early 2027, subject to Personalis shareholder approval, regulatory clearances and other customary closing conditions, including a termination right if Tempus Class A stock trades below $46.00.
The announcement highlights Personalis’ minimal residual disease business in a cited $20 billion market opportunity and preliminary Q2 revenue of $22.4 million, with 10,384 clinical tests delivered and a 33% quarter-over-quarter increase in test volumes.
Tempus AI, Inc. officer Ryan Fukushima (CEO, Data) reported spouse-related open-market sales of an aggregate 33,284 shares of Class A Common Stock on July 8, 2026. The shares were sold at weighted average prices between $56.80 and $59.47 per share, based on multiple trades within ranges from $56.10 to $60.11. Following these transactions, the filing lists 603,558 shares held directly and up to 167,763 shares held indirectly through the spouse. The sales were made under a Rule 10b5-1 trading plan adopted by the spouse on March 4, 2025.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting the proposed sale of 33,284 shares of Common Stock of TEM. The filing also discloses 10,000 shares sold on 07/06/2026 under a 10b5-1 plan for proceeds of $600,000.00.
Shares outstanding were 174,520,978 as of 07/08/2026, provided here as context.
Tempus AI, Inc. officer Fukushima Ryan reported an open-market sale of Class A Common Stock by his spouse under a pre-arranged Rule 10b5-1 trading plan. The spouse sold 10,000 shares at $60 per share and now indirectly holds 201,047 shares. Fukushima Ryan continues to hold 603,558 shares directly, indicating the transaction is a relatively small portion of the overall reported holdings.
TEM: Rule 144 notice reporting proposed sale of shares. The filing lists 10,000 shares of Common Stock as securities to be sold under a Restricted Stock Awards designation. The filing also reports sale activity of 13,550 shares on 05/19/2026 for $597,148.50.
The filing names a broker/dealer and gives an aggregate figure of $602,700.00 alongside the 10,000-share line. Timing and method details beyond the Rule 144 notice are not included in the excerpt.
Tempus AI, Inc. insider report: Entities associated with CEO and Chairman Eric P. Lefkofsky reported open‑market sales of a total of 166,250 shares of Class A Common Stock on June 29, 2026. The sales were executed by Blue Media, LLC and Gray Media, LLC at weighted average prices between $54.82 and $59.59 per share pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2025.
Following these transactions, Blue Media, LLC is shown holding 15,514,198 shares and Gray Media, LLC 8,806,216 shares of Tempus AI Class A Common Stock, with additional indirect holdings through foundations, LLCs and a 2025 GRAT, plus 2,230,721 shares held directly.
Tempus AI, Inc. director Jennifer A. Doudna reported an open-market sale of 2,673 shares of Class A Common Stock on June 25, 2026 at a price of $55.00 per share. After this transaction, she directly holds 25,942 shares of Tempus AI common stock.
The filing notes that this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by Doudna on August 12, 2025, indicating the transaction was scheduled in advance rather than timed opportunistically.